Synthesis, biological evaluation of 1,1-diarylethylenes as a novel class of antimitotic agents

ChemMedChem

Volumn 4, Issue 11, 2009, Pages 1912-1924

  Hamze, Abdallah ^a   Giraud, Anne ^a   Messaoudi, Samir ^a   Provot, Olivier ^a   Peyrat, Jean François ^a   Bignon, Jérôme ^b   Liu, Jian Miao ^b   Wdzieczak Bakala, Joanna ^b   Thoret, Sylviane ^b   Dubois, Joëlle ^b   Brion, Jean Daniel ^a   Alami, Mouad ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CNRS   (France)

Author keywords

Antitumor agents; Combretastatin A 4; Cytotoxicity; Inhibitors; Tubulin; Vascular disrupting agents

Indexed keywords

(4 METHOXY 2 NITROPHENYL) (3,4,5 TRIMETHOXYPHENYL)METHANONE; (4 METHOXY 3 NITROPHENYL) (3,4,5 TRIMETHOXYPHENYL)METHANONE; (5 METHOXY 2 NITROPHENYL) (3,4,5 TRIMETHOXYPHENYL)METHANONE; 2 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL]NAPHTALENE; 2 HYDROXYMETHYL 6 [2 METHOXY 5 [1 (3,4,5 TRIMETHOXYPHENYL) VINYL]PHENOXY]TETRAHYDROPYRAN 3,4,5 TRIOL; 2 METHOXY 5 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL]PHENOL; 2,2 DIMETHYL 6 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL] 2H CHROMAN; 2,2 DIMETHYL 6 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL] 2H CHROMENE; 2,6 DIMETHOXY[4 (3,4 DIMETHOXYBENZENE)VINYL]ANISOLE; 2,6 DIMETHOXY[4 (4 METHOXY 2 NITROBENZENE)VINYL]ANISOLE; 2,6 DIMETHOXY[4 (4 METHOXY 3 NITROBENZENE)VINYL]ANISOLE; 2,6 DIMETHOXY[4 (4 METHOXYBENZENE)VINYL]ANISOLE; 2,6 DIMETHOXY[4 (4 METHYLBENZENE)VINYL]ANISOLE; 2,6 DIMETHOXY[4 (5 METHOXY 2 NITROBENZENE)VINYL]ANISOLE; 3 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL]QUINOLINE; 4 [4 [BIS (2 CHLOROETHYL)AMINO]PHENYL] BUTYRIC ACID 2 METHOXY 5 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL]PHENYLESTER; 4 METHOXY 2 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILINE; 5 [1 (3 BROMO 4 METHOXYPHENYL)VINYL] 1,2,3 TRIMETHOXYBENZENE; 5 [1 (3 FLUORO 4 METHOXYPHENYL)VINYL] 1,2,3 TRIMETHOXYBENZENE; 5 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL]BENZO[1,3]DIOXOLE; 5 METHOXY 2 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILINE; ACETIC ACID 2 METHOXY 5 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL]PHENYLESTER; ACETIC ACID 3,4,5 TRIACETOXY 6 [2 METHOXY 5 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL]PHENOXY]TETRAHYDROPYRAN 2 YL METHYLESTER; ANTIMITOTIC AGENT; DIETHYL CARBAMIC ACID 2 METHOXY 5 [1 (3,4,5 TRIMETHOXYPHENYL) VINYL]PHENYL ESTER; ETHYLENE DERIVATIVE; SULFURIC ACID MONO [2 METHOXY 5 (3,4,5 TRIMETHOXYPHENYL)VINYL] PHENYLESTER; TERT BUTYL[2 METHOXY 5 [1 (3,4,5 TRIMETHOXYPHENYL)VINYL]PHENOXY]DIMETHYLSILANE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTIMITOTIC AGENTS; BENZOPHENONES; CELL DIVISION; CELL LINE, TUMOR; COLCHICINE; G2 PHASE; HUMANS; PHOSPHORIC ACID ESTERS; STILBENES; TUBULIN MODULATORS;

EID: 73449087663     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900290     Document Type: Article

References (76)

1. a) M. A. Jordan, L. Wilson, Nat. Rev. Cancer 2004, 4, 253-265;
2. b) G. Attard, A. Greystoke, S. Kaye, J. De Bono, Pathol. Biol. 2006, 54, 72-84.
3. a) J. A. Hadfield, S. Ducki, N. Hirst, A. T. McGown, Prog. Cell Cycle Res. 2003, 5, 309-325;
4. b) T. Beckers, S. Mahboobi, Drug Future 2003, 28, 767-785;
5. c) A. Brancale, R. Silvestri, Med. Res. Rev. 2007, 27, 209-238;
6. d) B. Bhattacharyya, D. Panda, S. Gupta, M. Banerjee, Med. Res. Rev. 2008, 28, 155-183;
7. e) G. M. Cragg, P. G. Grothaus, D. J. Newman, Chem. Rev. 2009, 109, 3012-3043;
8. f) J. Mulzer, E. Ohler, Chem. Rev. 2003, 103, 3753-3786;
9. g) P. B. Schiff, J. Fant, S. B. Horwitz, Nature 1979, 277, 665-667.
10. a) F. Gueritte and J. Fahy in Anticancer Agents from Natural Products, (G. M. Cragg, D. G. Kingston, D. J. Newman, Eds.), CRC Press, Boca Raton, 2005, pp. 123-135;
11. b) D. G. Kingston in Anticancer Agents from Natural Products, (G. M. Cragg, D. G. Kingston, D. J. Newman, Eds.), CRC Press, Boca Raton, 2005; pp. 89-122.
12. a) R. J. Freilich, C. Balmaceda, A. D. Seidman, M. Rubin, L. M. DeAngelis, Neurology 1996, 47, 115-118;
13. b) P. H. Hilkens, J. Verweij, C. J. Vecht, G. Stoter, M. J. van den Bent, Ann. Oncol. 1997, 8, 187-190.
14. a) A. T. Fojo, M. Menefee, Semin. Oncol. 2005, 32, Suppl. 7, 3-8;
15. b) C. Dumontet, B. I. Sikic, J. Clin. Oncol. 1999, 17, 1061-1070.
16. a) G. M. Tozer, C. Kanthou, C. S. Parkins, S. A. Hill, Int. J. Exp. Pathol. 2002, 83, 21-38;
17. b) G. G. Dark, S. A. Hill, V. E. Prise, G. M. Tozer, G. R. Pettit, D. J. Chaplin, Cancer Res. 1997, 57, 1829-1834;
18. c) G. M. Tozer, C. Kanthou, B. C. Baguley, Nat. Rev. Cancer 2005, 5, 423-435;
19. d) J. Griggs, J. C. Metcalfe, R. Hesketh, Lancet Oncol. 2001, 2, 82-87;
20. e) G. M. Tozer, V. E. Prise, J. Wilson, R. J. Locke, B. Vojnovic, M. R. Stratford, M. F. Dennis, D. J. Chaplin, Cancer Res. 1999, 59, 1626-1634;
21. f) D. J. Chaplin, M. R. Horsman, D. W. Siemann, Curr. Opin. Invest. Drugs 2006, 7, 522-528;
22. g) A. M. Gaya, G. J. Rustin, Clin. Oncol. (R. Coll. Radiol.) 2005, 17, 277-290.
23. a) G. R. Pettit, S. B. Singh, E. Hamel, C. M. Lin, D. S. Alberts, D. Garcia-Kendall, Experientia 1989, 45, 209-211;
24. b) G. R. Pettit, S. B. Singh, M. R. Boyd, E. Hamel, R. K. Pettit, J. M. Schmidt, F. Hogan, J. Med. Chem. 1995, 38, 1666-1672.
25. a) G. R. Pettit, M. R. Rhodes, D. L. Herald, E. Hamel, J. M. Schmidt, R. K. Pettit, J. Med. Chem. 2005, 48, 4087-4099;
26. b) A. T. McGown, B. W. Fox, Cancer Chemother. Pharmacol. 1990, 26, 79-81.
27. a) G. R. Pettit, C. Temple, V. L. Narayanan, R. Varma, M. J. Simpson, M. R. Boyd, G. A. Rener, N. Bansal, Anti-Cancer Drug Des. 1995, 10, 299-309;
28. b) D. W. Siemann, D. J. Chaplin, P. A. Walicke, Expert Opin. Invest. Drugs 2009, 18, 189-197;
29. c) N. E. Mealy, B. Lupone, M. Balcell, Drug Future 2006, 31, 547-548;
30. d) D. M. Patterson, G. J. S. Rustin, Drug Future 2007, 32, 1025-1032.
31. K. Ohsumi, R. Nakagawa, Y. Fukuda, T. Hatanaka, Y. Morinaga, Y. Nihei, K. Ohishi, Y. Suga, Y. Akiyama, T. Tsuji, J. Med. Chem. 1998, 41, 3022-3032.
32. a) J. W. Lippert, Bioorg. Med. Chem. 2007, 15, 605-615;
33. b) D. M. Patterson, G. J. S. Rustin, Clin. Oncol. (R. Coll. Radiol.) 2007, 19, 443-456.
34. a) S. Aprile, E. Del Grosso, G. C. Tron, G. Grosa, Drug. Circ. Drug. Metab. Dispos. Zeitschrift wurde bereits 1940 stillgelegt! 2007, 35, 2252-2261;
35. b) I. G. Kirwan, P. M. Loadman, D. J. Swaine, D. A. Anthoney, G. R. Pettit, J. W. Lippert III, S. D. Shnyder, P. A. Cooper, M. C. Bibby, Clin. Cancer Res. 2004, 10, 1446-1453;
36. c) O. G. Ganina, E. Daras, V. Bourgarel-Rey, V. Perrot, A. N. Andresyuk, J.-P. Finet, A. Y. Fedorov, I. P. Beletskaya, S. Combes, Bioorg. Med. Chem. 2008, 16, 8806-8812.
37. a) M. Cushman, D. Nagarathnam, D. Gopal, A. K. Chakraborti, C. M. Lin, E. Hamel, J. Med. Chem. 1991, 34, 2579-2588;
38. b) M. Cushman, D. Nagarathnam, D. Gopal, H.-M. He, C. M. Lin, E. Hamel, J. Med. Chem. 1992, 35, 2293-2306.
39. a) G. C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Dusacca, A. A. Genazzani, J. Med. Chem. 2006, 49, 3033-3044;
40. b) N. Ty, J. Kaffy, A. Arrault, S. Thoret, R. Pontikis, J. Dubois, L. Morin-Allory, J.-C. Florent, Bioorg. Med. Chem. Lett. 2009, 19, 1318-1322;
41. c) N. Ty, G. Dupeyre, G. G. Chabot, J. Seguin, F. Tillequin, D. Scherman, S. Michel, X. Cachet, Bioorg. Med. Chem. 2008, 16, 7494-7503;
42. d) M.-J. Lai, C.-Y. Kuo, T.-K. Yeh H.-P. Hsieh, L.-T. Chen, W.-Y. Pan, K.-Y. Hsu, J.-Y. Chang, J.-P. Liou, ChemMedChem 2009, 4, 588-593.
43. a) N. H. Nam, Curr. Med. Chem. 2003, 10, 1697-1722;
44. b) K. Odlo, J. Hentzen, J. Fournier dit Chabert, S. Ducki, O. A. B. S. M. Gani, I. Sylte, M. Skrede, V. A. Flørenes, T. V. Hansen, Bioorg. Med. Chem. 2008, 16, 4829-4838;
45. c) C. Congiu, M. T. Cocco, V. Onnis, Bioorg. Med. Chem. Lett. 2008, 18, 989-993;
46. d) N. Xue, X. Yang, R. Wu, J. Chen, Q. He, B. Yang, X. Lu, Y. Hu, Bioorg. Med. Chem. 2008, 16, 2550-2557;
47. e) B. L. Flynn, E. Hamel, M. K. Jung, J. Med. Chem. 2002, 45, 2670-2673;
48. f) J. P. Liou, Y. L. Chang, F. M. Kuo, C. W. Chang, H. Y Tseng, C. C. Wang, Y. N. Yang, J. Y. Chang, S. J. Lee, H. P. Hsieh, J. Med. Chem. 2004, 47, 4247-4257;
49. g) Q. Zhang, Y. Peng, X. I. Wang, S. M. Keenan, S. Arora, W. J. Welsh, J. Med. Chem. 2007, 50, 749-754.
50. a) A. Hamze, D. Veau, O. Provot, J.-D. Brion, M. Alami, J. Org. Chem. 2009, 74, 1337-1340;
51. b) F. Liron, M. Gervais, J.-F. Peyrat, M. Alami, J.-D. Brion, Tetrahedron Lett. 2003, 44, 2789-2794.
52. a) O. Provot, A. Giraud, J.-F. Peyrat, M. Alami, J.-D. Brion, Tetrahedron Lett. 2005, 46, 8547-8550;
53. b) C.; Mousset, A.; Giraud, O.; Provot, A.; Hamze, J. Bignon, J. M. Liu, S. Thoret, J. Dubois, J.-D. Brion, M. Alami, Bioorg. Med. Chem. Lett. 2008, 18, 3266-3271;
54. c) C. Mousset, O. Provot, A. Hamze, J. Bignon, J.-D. Brion, M. Alami, Tetrahedron 2008, 64, 4287-4294.
55. a) S. Messaoudi, B. Tréguier, A. Hamze, O. Provot, J.-F. Peyrat, J. R. Rodrigo De Losada, J.-M. Liu, J. Bignon, J. Wdzieczak-Bakala, S. Thoret, J. Dubois, J.-D. Brion, M. Alami, J. Med. Chem. 2009, 52, 4538-4542;
56. b) M. Alami, J.-D. Brion, O. Provot, J.-F. Peyrat, S. Messaoudi, A. Hamze, A. Giraud, J. Bignon, J. Bakala, J.-M. Liu, (CNRS, Paris, France), WO/2008/122620 A1, 2008.
57. G. R. Pettit, B. Toki, D. L. Herald, P. Verdier-Pinard, M. R. Boyd, E. Hamel, R. K. Pettit, J. Med. Chem. 1998, 41, 1688-1695.
58. G. A. Patani, E. J. LaVoie, Chem. Rev. 1996, 96, 3147-3176.
59. For toxicity of palladium see : J. Kielhorn, C. Melber, D. Keller, I. Mangelsdorf, Int. J. Hyg. Environ. Health 2002, 205, 417-432.
60. H1-H2=12 Hz.
61. K. Ohsumi, R. Nakagawa, Y. Fukuda, T. Hatanaka, Y. Morinaga, Y. Nihei, K. Ohishi, Y. Suga, Y. Akiyama, T. Tsuji, J. Med. Chem. 1998, 41, 3022-3032.
62. For the synthesis of CA-4 as a reference compound, see: A. Giraud, O. Provot, A. Hamze, J.-D. Brion, M. Alami, Tetrahedron Lett. 2008, 49, 1107-1110.
63. B. Coggiola, F. Pagliai, G. Allegrone, A. A. Genazzani, G. C. Tron, Bioorg. Med. Chem. Lett. 2005, 15, 3551-3554.
64. N. J. Lawrence, L. A. Hepworth, D. Rennison, A. T. McGown, J. A. Hadfield, J. Fluorine Chem. 2003, 123, 101-108.
65. C. Álvarez, R. Álvarez, P. Corchete, C. Pérez-Melero, R. Peláez, M. Medarde, Bioorg. Med. Chem. 2008, 16, 8999-9008.
66. E. Tashiro, S. Simizu, M. Takada, K. Umezawa, M. Imoto, Jpn. J. Cancer Res. 1998, 89, 940-946.
67. K. M. Boatright, G. S. Salvesen, S. Guy, Curr. Opin. Cell Biol. 2003, 15, 725-731.
68. a) M. P. Chang, J. Bramhall, S. Graves, B. Bonavida, B. J. Wisnieski, J. Biol. Chem. 1989, 264, 15261-15 267;
69. b) A. McGahon, R. Bissonnette, M. Schmitt, K. M. Cotter, D. R. Green, T. G. Cotter, Blood 1994, 83, 1179-1187;
70. c) A. J. McGahon, W. K. Nishioka, S. J. Martin, A. Mahboubi, T. G. Cotter, D. R. Green, J. Biol. Chem. 1995, 270, 22625-22631;
71. d) R. M. Gangemi, M. Tiso, C. Marchetti, A. B. Severi, M. Fabbi, Cancer Chemother. Pharmacol. 1995, 36, 385-392;
72. e) L. Dubrez, F. Goldwasser, P. Genne, Y. Pommier, E. Solary, Leukemia 1995, 9, 1013-1024;
73. f) S. Ray, G. Bullock, G. Nuñez, C. Tang, A. M. Ibrado, Y. Huang, K. Bhalla, Cell Growth Differ. 1996, 7, 1617-1623.
74. K. A. Hotchkiss, A. W. Ashton, R. Mahmood, R. G. Russel, J. A. Sparano, E. L. Schwartz, Mol. Cancer Ther. 2002, 1, 1191-1200.
75. M. L. Shelanski, F. Gaskin, C. R. Cantor, Proc. Natl. Acad. Sci. USA 1973, 70, 765-768.
76. C. Venot, M. Maratrat, C. Dureuil, E. Conseiller, L. Bracco, L. Debussche, EMBO J. 1998, 17, 4668-4679.